A Small Molecule Promoting Neural Differentiation Suppresses Cancer Stem Cells in Colorectal Cancer.
Jung Kyu ChoiIhn-Sil KwakSae-Bom YoonHeeyeong ChoByoung-San MoonPublished in: Biomedicines (2022)
Cancer stem cells (CSCs) are a tumor cell subpopulation that drives tumor progression and metastasis, leading to a poor overall survival of patients. In colorectal cancer (CRC), the hyper-activation of Wnt/β-catenin signaling by a mutation of both adenomatous polyposis coli (APC) and K-Ras increases the size of the CSC population. We previously showed that CPD0857 inactivates Wnt/β-catenin signaling by promoting the ubiquitin-dependent proteasomal degradation of β-catenin and Ras proteins, thereby decreasing proliferation and increasing the apoptosis of CRC lines. CPD0857 also decreased the growth and invasiveness of CRC cells harboring mutant K-Ras resistant to EGFR mAb therapy. Here, we show that CPD0857 treatment decreases proliferation and increases the neuronal differentiation of neural progenitor cells (NPCs). CDP0857 effectively reduced the expression of CSC markers and suppressed self-renewal capacity. CPD0857 treatment also inhibited the proliferation and expression of CSC markers in D- K-Ras MT cells carrying K-Ras , APC and PI3K mutations, indicating the inhibition of PI3K/AKT signaling. Moreover, CPD0857-treated xenograft mice showed a regression of tumor growth and decreased numbers of CSCs in tumors. We conclude that CPD0857 could serve as the basis of a drug development strategy targeting CSCs activated through Wnt/β-catenin-Ras MAPK-PI3K/AKT signaling in CRCs.
Keyphrases
- pi k akt
- cell cycle arrest
- cancer stem cells
- signaling pathway
- wild type
- cell proliferation
- induced apoptosis
- epithelial mesenchymal transition
- small molecule
- poor prognosis
- cell death
- stem cells
- newly diagnosed
- small cell lung cancer
- end stage renal disease
- escherichia coli
- oxidative stress
- tyrosine kinase
- type diabetes
- chronic kidney disease
- epidermal growth factor receptor
- cell therapy
- prognostic factors
- protein protein
- mesenchymal stem cells
- peritoneal dialysis
- metabolic syndrome
- patient reported outcomes
- skeletal muscle